2-[hydroxy-[(2S)-2-hydroxy-3-octadecanoyloxypropoxy]phosphoryl]oxyethyl-trimethylazanium

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 甘油磷脂
• 英文名称: 2-[hydroxy-[(2S)-2-hydroxy-3-octadecanoyloxypropoxy]phosphoryl]oxyethyl-trimethylazanium
• 化学式: C26H55NO7P+
• 分子量: 524.7
• InChiKey: IHNKQIMGVNPMTC-VWLOTQADSA-O

计算性质

• 辛醇/水分配系数(LogP)：
  6.7
• 重原子数：
  35
• 可旋转键数：
  26
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.96
• 拓扑面积：
  102
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• Acoustic driven drug delivery systems
  申请人：UNIVERSITY OF OTAGO

  公开号：US11260126B2

  公开（公告）日：2022-03-01

  The present invention provides acoustically activated liposome compositions for use as drug delivery vehicles, and to methods for drug release and drug delivery for therapeutic applications.

  本发明提供了用作给药载体的声学活化脂质体组合物，以及用于治疗的药物释放和给药方法。
• [EN] BIOMARKER IN OSSOTIDE INTERVENTION THERAPY OF OSTEOPOROSIS, SCREENING METHOD, AND USE<br/>[FR] BIOMARQUEUR DANS UNE THÉRAPIE D'INTERVENTION D'OSSOTIDE DE L'OSTÉOPOROSE, PROCÉDÉ DE CRIBLAGE ET UTILISATION<br/>[ZH] 骨肽干预治疗骨质疏松中的生物标志物、筛选方法及用途
  申请人：INSTITUTE OF FOOD SCIENCE AND TECH CHINESE ACADEMY OF AGRICULTURAL SCIENCES

  公开号：WO2021114717A1

  公开（公告）日：2021-06-17

  骨肽干预治疗骨质疏松中的生物标志物、生物标志物的筛选方法及其用途。生物标志物包括脂类和类脂分子、有机酸及其衍生物和/或神经递质类物质，脂类和类脂分子为以下物质的任一种或几种：牛磺酸、花生四烯酸、1-棕榈酰-2-羟基-sn-甘油-3-磷酸乙醇胺、(4Z,7Z,10Z,13Z,16Z,19Z)-4,7,10,13,16,19-二十二碳六烯酸、1-硬脂酰-2-羟基-sn-甘油-3-磷酸胆碱、牛磺酸脱氧胆酸、牛磺去氧胆酸和牛磺胆。
• PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS
  申请人：GRI Bio, Inc.

  公开号：EP3229811B1

  公开（公告）日：2021-02-24
• Means and Methods for the Treatment and Prevention of Allergic Diseases
  申请人：Braxmeier Tobias

  公开号：US20090018105A1

  公开（公告）日：2009-01-15

  The present invention relates of the use of certain inner ionic (zwitter ionic) phospholipids, phosphonolipids and phosphate derivatives for the preparation of a pharmaceutical composition for the treatment, prevention and/or amelioration of an immunological disorder related to mast cell sensitization. Preferred in this context are edelfosine and miltefosine. In a particularly preferred embodiment, the present invention relates to the use of miltefosine for the preparation of a pharmaceutical composition for the treatment, prevention and/or amelioration of allergic diseases, in particular acute hyperallergic diseases, like asthma.
• METHODS FOR THE TREATMENT AND AMELIORATION OF ATOPIC DERMATITIS
  申请人：BRAXMEIER Tobias

  公开号：US20110263531A1

  公开（公告）日：2011-10-27

  The present invention relates of the use of certain inner ionic (zwitter ionic) phospholipids, phosphonolipids and phosphate derivatives for the preparation of a pharmaceutical composition for the treatment, prevention and/or amelioration of an immunological disorder related to mast cell sensitization and/or activation. Preferred in this context are Edelfosine, Miltefosine and Perifosine. In a particularly preferred embodiment, the present invention relates to the use of Miltefosine for the preparation of a pharmaceutical composition for the treatment, prevention and/or amelioration of allergic diseases, in particular acute hyperallergic diseases, like asthma, atopic dermatitis and mastocytosis.